Mechanisms of Inactivation of P14arf, P15ink4b, and P16ink4a Genes in Human Esophageal Squamous Cell Carcinoma1

Total Page:16

File Type:pdf, Size:1020Kb

Mechanisms of Inactivation of P14arf, P15ink4b, and P16ink4a Genes in Human Esophageal Squamous Cell Carcinoma1 2704 Vol. 5, 2704–2713, October 1999 Clinical Cancer Research Advance and Briefs Mechanisms of Inactivation of p14ARF, p15INK4b, and p16INK4a Genes in Human Esophageal Squamous Cell Carcinoma1 Eric Poe Xing,2 Yan Nie,2 Yunlong Song, rations in the p16INK4a locus. Our results show that in hu- ARF Guang-Yu Yang, Yuyang Christine Cai, man ESCCs, p14 is a primary target of homozygous deletion along with p15INK4b, whereas p16INK4a is the hotspot Li-Dong Wang, and Chung S. Yang3 of hypermethylation of the 9p21 gene cluster. The frequent Laboratory for Cancer Research, College of Pharmacy, Rutgers, The inactivation of the p14ARF and p16INK4a genes may be an State University of New Jersey, Piscataway, New Jersey 08854-8020 [E. P. X., Y. N., Y. S., G-Y. Y., Y. C. C., C. S. Y.], and Henan important mechanism for the dysfunction of both the Rb Medical University, Zhengzhou, Henan, 457500 China [L-D. W.] and p53 growth regulation pathways during ESCC develop- ment. Abstract Introduction The 9p21 gene cluster, harboring growth suppressive The 9p21 chromosomal band is one of the most frequently genes p14ARF, p15INK4b, and p16INK4a, is one of the major altered genomic regions in human cancers (1). Within a short aberration hotspots in human cancers. It was shown that distance of ;50 kb, this region harbors a gene cluster consisting of p14ARF and p16INK4a play active roles in the p53 and Rb three genes, p14ARF, p15INK4b, and p16INK4a, all of which have tumor suppressive pathways, respectively, and p15INK4b is a putative tumor suppressor roles (2). In addition to physical prox- mediator of the extracellular growth inhibition signals. To imity, the genomic structures of these genes are remarkably inter- elucidate specific targets and aberrations affecting this sub- related (Fig. 1). p14ARF and p16INK4a transcripts are produced via chromosomal region, we constructed a detailed alteration utilization of a common coding sequence for exons 2 and 3, map of the 9p21 gene cluster by analyzing homozygous together with distinct sequences for promoter and exon 1 (3). deletion, hypermethylation, and mutation of the p14ARF, However, the resulting proteins are completely different because p15INK4b, and p16INK4a genes individually in 40 esophageal different reading frames are used for the respective translation squamous cell carcinomas (ESCCs) and compared the ge- processes (4). The conservation in mammalian genome of this netic alterations with mRNA expression in 18 of these sam- unique gene structure, usually seen in primitive organisms subject ples. We detected aberrant promoter methylation of the to genome size constrains, suggests either the possible ancient p16INK4a gene in 16 (40%), of p14ARF in 6 (15%), and of origin or the biological essentialness of the unitary inheritance of p15INK4b in 5 (12.5%) tumor samples. Most p16INK4a methy- these two genes. p15INK4b is highly homologous to p16INK4a, lations were exclusive, whereas all but one of the p14ARF/ particularly in exon 2, where they share 91% sequence identity (5), p15INK4b methylations were accompanied by concomitant indicating their origination by a gene duplication event. The 9p21 p16INK4a methylation. We detected homozygous deletion of gene cluster is the first of its kind identified in the human genome p16INK4a in 7 (17.5%), of p14ARF-E1b in 13 (33%), and of associated with multiple tumor suppressor activities. Besides its p15INK4b in 16 (40%) tumor samples. Most deletions oc- functional importance in regulating cell proliferation, which makes curred exclusively on the E1b-p15INK4b loci. Two samples this gene cluster a target of selective inactivation during carcino- contained p14ARF deletion but with p16INK4a and p15INK4b genic process, there may be a physical basis underlining its frequent intact. No mutation was detected in the p14ARF and p16INK4a disruption in cancer. It was reported that at least two tightly clus- genes. Comparative RT-PCR showed good concordance be- tered breakpoints exist within the cluster, the sequence context of tween suppressed mRNA expression and genetic alteration which potentially facilitates illegitimate V(D)J recombinase activ- for p15INK4b and p16INK4a genes in the 18 frozen samples, ities (6). Furthermore, the promoter regions of all three genes are whereas 5 of the 13 cases with suppressed p14ARF mRNA highly abundant with CpG islands that are susceptible to hyperm- expression contained no detectable E1b alteration but aber- ethylation (7). It is intriguing why presumably important genes are clustered in such a manner that renders high susceptibility to genetic alterations. Recent studies have revealed that p14ARF and p16INK4a Received 4/26/99; revised 8/2/99; accepted 8/2/99. play active roles in the p53 and Rb growth-control pathways, The costs of publication of this article were defrayed in part by the respectively (Fig. 1; Ref. 8). p16INK4a is a cyclin-dependent payment of page charges. This article must therefore be hereby marked kinase inhibitor functioning upstream Rb. It can negatively advertisement in accordance with 18 U.S.C. Section 1734 solely to regulate cell cycle progression by preventing the phosphoryla- indicate this fact. ARF 1 Supported by NIH Grant CA65781, facilities from National Institute of tion (inactivation) of Rb during G1 phase (9). p14 restrains Environmental Health Sciences Center Grant ES 05022, National Can- cell growth by abrogating Mdm2 inhibition of the p53 activity, cer Institute Cancer Center Supporting Grant CA 72030, and National and therefore facilitates p53 mediated cell cycle arrest and Natural Science Foundation of China (39840012). apoptosis (10). It was demonstrated that oncogenic Ras elicits an 2 These authors contributed equally to this study. 3 anti-tumorigenic response mediated by the up-regulation of both To whom requests for reprints should be addressed, at Laboratory for ARF INK4a Cancer Research, College of Pharmacy, Rutgers University, Piscataway, p14 and p16 , which in turn activate the tumor suppres- NJ 08854-8020. Phone: (732) 445-5360; Fax: (732) 445-0687. sors p53 and pRb, respectively (11, 12). Recent study further Clinical Cancer Research 2705 Fig. 1 Genomic organization of the 9p21 gene cluster and schematic de- scription of the involvement of p14ARF, p15INK4b, and p16INK4a gene products in the pRb and p53 antitumorigenetic pathways [based on a diagram that ap- peared in Robertson et al. (7)]. Solid lines, regulatory steps of each pathway; dashed lines, cross-talk between the pRb and p53 pathways. showed that p14ARF provides a failsafe mechanism for defective deletion, whereas p15INK4b was frequently homozygously de- Rb pathway by its inducibility via deregulated E2F-1 activity leted and occasionally methylated (20). This pattern is different resulted from Rb inactivation (13). Compared with p14ARF and from reports on other types of cancers identifying p16INK4a as p16INK4a, p15INK4b is less prominent as a tumor suppressor. In the main deletion target and p15INK4b as a bystander, which contrast to p16INK4a, which is activated by intracellular stimuli, possibly play a small part in the tumor suppressor role (2). In p15INK4b suppresses cell growth in response to extracellular light of the recent elucidation of the tumor suppressor role of stimuli such as TGF-b (5). p14ARF, the first exon of which is only 12 kb downstream of the Inactivation of the Rb and p53 tumor suppressor pathways p15INK4b gene, and the presence of evidence of exclusive dele- is observed in most human cancers (1). By virtue of its close tion of p14ARF-E1b with the retention of both p15INK4b and involvement in both pathways, the p14ARF-p15INK4b-p16INK4a p16INK4a in T-cell acute lymphoblastic leukemia (21), we sus- gene cluster at chromosome 9p21 may be a nexus of the cellular pect that our previous result may indicate p14ARF-E1b as being growth-control network, the inactivation of which results in a primary target for inactivation in ESCCs. In consideration of collapse of the tumor suppression system. To date, a vast this point, we thought it is necessary to investigate whether amount of data has demonstrated multiple types of genetic genomic alterations indeed associate with altered gene expres- alterations on the 9p21 region, the prevalence of which varies sions in ESCCs. In the present study, we constructed a detailed with the type of tumors. For example, large homozygous dele- alteration map of the 9p21 gene cluster by analyzing the ho- tions are common in head and neck tumors, bladder carcinomas, mozygous deletion and aberrant methylation of the p14ARF, and malignant gliomas (14–16). Transcriptional-inactivating p15INK4b, and p16INK4a genes individually in 40 resected ESCC promoter methylation was common in breast and colon cancer samples and analyzed the mRNA expression pattern of the for the p16INK4a gene (17) and in leukemia for p15INK4b (17, respective genes in 18 frozen samples. We show that suppressed 18). Recently, Robertson et al. (7) identified that the promoter of mRNA expression occurred at a high frequency for all three p14ARF gene is a CpG island and observed its hypermethylation genes in primary ESCCs, and homozygous deletion is the pri- in colon cancer cell lines, which was responsible for the gene mary cause leading to such inactivation for the p14ARF and inactivation (7). Point mutation and small deletion of the p15INK4b genes, whereas aberrant methylation is the main event p16INK4a locus was common in pancreatic adenocarcinoma, underlining p16INK4a inactivation. biliary tract cancers, and hereditary melanoma (reviewed in Ref. INK4a ARF 19) and affected p16 exclusively or together with p14 Materials and Methods (4). Despite the ample evidence of the 9p21 gene cluster as a ESCC Specimen Preparation and RNA/DNA Extrac- frequent tumor target, it is not known whether all three genes in tion. Eighteen primary ESCC specimens, together with their the cluster are indiscriminately affected in a tumor and whether adjacent normal epithelial tissues, were collected from patients all of the genes are uniformly disrupted by the same mechanism. in Linzhou City (formerly Linxian) of northern China, a well- We reported previously an alteration pattern of the 9p21 recognized high-risk area for ESCC.
Recommended publications
  • The Retinoblastoma Tumor-Suppressor Gene, the Exception That Proves the Rule
    Oncogene (2006) 25, 5233–5243 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc REVIEW The retinoblastoma tumor-suppressor gene, the exception that proves the rule DW Goodrich Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA The retinoblastoma tumor-suppressor gene (Rb1)is transmission of one mutationally inactivated Rb1 allele centrally important in cancer research. Mutational and loss of the remaining wild-type allele in somatic inactivation of Rb1 causes the pediatric cancer retino- retinal cells. Hence hereditary retinoblastoma typically blastoma, while deregulation ofthe pathway in which it has an earlier onset and a greater number of tumor foci functions is common in most types of human cancer. The than sporadic retinoblastoma where both Rb1 alleles Rb1-encoded protein (pRb) is well known as a general cell must be inactivated in somatic retinal cells. To this day, cycle regulator, and this activity is critical for pRb- Rb1 remains an exception among cancer-associated mediated tumor suppression. The main focus of this genes in that its mutation is apparently both necessary review, however, is on more recent evidence demonstrating and sufficient, or at least rate limiting, for the genesis of the existence ofadditional, cell type-specific pRb func- a human cancer. The simple genetics of retinoblastoma tions in cellular differentiation and survival. These has spawned the hope that a complete molecular additional functions are relevant to carcinogenesis sug- understanding of the Rb1-encoded protein (pRb) would gesting that the net effect of Rb1 loss on the behavior of lead to deeper insight into the processes of neoplastic resulting tumors is highly dependent on biological context.
    [Show full text]
  • DNA Microarrays (Gene Chips) and Cancer
    DNA Microarrays (Gene Chips) and Cancer Cancer Education Project University of Rochester DNA Microarrays (Gene Chips) and Cancer http://www.biosci.utexas.edu/graduate/plantbio/images/spot/microarray.jpg http://www.affymetrix.com Part 1 Gene Expression and Cancer Nucleus Proteins DNA RNA Cell membrane All your cells have the same DNA Sperm Embryo Egg Fertilized Egg - Zygote How do cells that have the same DNA (genes) end up having different structures and functions? DNA in the nucleus Genes Different genes are turned on in different cells. DIFFERENTIAL GENE EXPRESSION GENE EXPRESSION (Genes are “on”) Transcription Translation DNA mRNA protein cell structure (Gene) and function Converts the DNA (gene) code into cell structure and function Differential Gene Expression Different genes Different genes are turned on in different cells make different mRNA’s Differential Gene Expression Different genes are turned Different genes Different mRNA’s on in different cells make different mRNA’s make different Proteins An example of differential gene expression White blood cell Stem Cell Platelet Red blood cell Bone marrow stem cells differentiate into specialized blood cells because different genes are expressed during development. Normal Differential Gene Expression Genes mRNA mRNA Expression of different genes results in the cell developing into a red blood cell or a white blood cell Cancer and Differential Gene Expression mRNA Genes But some times….. Mutations can lead to CANCER CELL some genes being Abnormal gene expression more or less may result
    [Show full text]
  • P14ARF Inhibits Human Glioblastoma–Induced Angiogenesis by Upregulating the Expression of TIMP3
    P14ARF inhibits human glioblastoma–induced angiogenesis by upregulating the expression of TIMP3 Abdessamad Zerrouqi, … , Daniel J. Brat, Erwin G. Van Meir J Clin Invest. 2012;122(4):1283-1295. https://doi.org/10.1172/JCI38596. Research Article Oncology Malignant gliomas are the most common and the most lethal primary brain tumors in adults. Among malignant gliomas, 60%–80% show loss of P14ARF tumor suppressor activity due to somatic alterations of the INK4A/ARF genetic locus. The tumor suppressor activity of P14ARF is in part a result of its ability to prevent the degradation of P53 by binding to and sequestering HDM2. However, the subsequent finding of P14ARF loss in conjunction with TP53 gene loss in some tumors suggests the protein may have other P53-independent tumor suppressor functions. Here, we report what we believe to be a novel tumor suppressor function for P14ARF as an inhibitor of tumor-induced angiogenesis. We found that P14ARF mediates antiangiogenic effects by upregulating expression of tissue inhibitor of metalloproteinase–3 (TIMP3) in a P53-independent fashion. Mechanistically, this regulation occurred at the gene transcription level and was controlled by HDM2-SP1 interplay, where P14ARF relieved a dominant negative interaction of HDM2 with SP1. P14ARF-induced expression of TIMP3 inhibited endothelial cell migration and vessel formation in response to angiogenic stimuli produced by cancer cells. The discovery of this angiogenesis regulatory pathway may provide new insights into P53-independent P14ARF tumor-suppressive mechanisms that have implications for the development of novel therapies directed at tumors and other diseases characterized by vascular pathology. Find the latest version: https://jci.me/38596/pdf Research article P14ARF inhibits human glioblastoma–induced angiogenesis by upregulating the expression of TIMP3 Abdessamad Zerrouqi,1 Beata Pyrzynska,1,2 Maria Febbraio,3 Daniel J.
    [Show full text]
  • Review Article PTEN Gene: a Model for Genetic Diseases in Dermatology
    The Scientific World Journal Volume 2012, Article ID 252457, 8 pages The cientificWorldJOURNAL doi:10.1100/2012/252457 Review Article PTEN Gene: A Model for Genetic Diseases in Dermatology Corrado Romano1 and Carmelo Schepis2 1 Unit of Pediatrics and Medical Genetics, I.R.C.C.S. Associazione Oasi Maria Santissima, 94018 Troina, Italy 2 Unit of Dermatology, I.R.C.C.S. Associazione Oasi Maria Santissima, 94018 Troina, Italy Correspondence should be addressed to Carmelo Schepis, [email protected] Received 19 October 2011; Accepted 4 January 2012 Academic Editors: G. Vecchio and H. Zitzelsberger Copyright © 2012 C. Romano and C. Schepis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. PTEN gene is considered one of the most mutated tumor suppressor genes in human cancer, and it’s likely to become the first one in the near future. Since 1997, its involvement in tumor suppression has smoothly increased, up to the current importance. Germline mutations of PTEN cause the PTEN hamartoma tumor syndrome (PHTS), which include the past-called Cowden, Bannayan- Riley-Ruvalcaba, Proteus, Proteus-like, and Lhermitte-Duclos syndromes. Somatic mutations of PTEN have been observed in glioblastoma, prostate cancer, and brest cancer cell lines, quoting only the first tissues where the involvement has been proven. The negative regulation of cell interactions with the extracellular matrix could be the way PTEN phosphatase acts as a tumor suppressor. PTEN gene plays an essential role in human development. A recent model sees PTEN function as a stepwise gradation, which can be impaired not only by heterozygous mutations and homozygous losses, but also by other molecular mechanisms, such as transcriptional regression, epigenetic silencing, regulation by microRNAs, posttranslational modification, and aberrant localization.
    [Show full text]
  • Wnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response
    International Journal of Molecular Sciences Review Wnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response Casey D. Stefanski 1,2 and Jenifer R. Prosperi 1,2,3,* 1 Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46617, USA; [email protected] 2 Mike and Josie Harper Cancer Research Institute, South Bend, IN 46617, USA 3 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine-South Bend, South Bend, IN 46617, USA * Correspondence: [email protected]; Tel.: +1-574-631-4002 Received: 30 September 2020; Accepted: 20 October 2020; Published: 22 October 2020 Abstract: Resistance to chemotherapy occurs through mechanisms within the epithelial tumor cells or through interactions with components of the tumor microenvironment (TME). Chemoresistance and the development of recurrent tumors are two of the leading factors of cancer-related deaths. The Adenomatous Polyposis Coli (APC) tumor suppressor is lost in many different cancers, including colorectal, breast, and prostate cancer, and its loss correlates with a decreased overall survival in cancer patients. While APC is commonly known for its role as a negative regulator of the WNT pathway, APC has numerous binding partners and functional roles. Through APC’s interactions with DNA repair proteins, DNA replication proteins, tubulin, and other components, recent evidence has shown that APC regulates the chemotherapy response in cancer cells. In this review article, we provide an overview of some of the cellular processes in which APC participates and how they impact chemoresistance through both epithelial- and TME-derived mechanisms. Keywords: adenomatous polyposis coli; chemoresistance; WNT signaling 1.
    [Show full text]
  • Teacher Background on P53 Tumor Suppressor Protein
    Cancer Lab p53 – Teacher Background on p53 Tumor Suppressor Protein Note: The Teacher Background Section is meant to provide information for the teacher about the topic and is tied very closely to the PowerPoint slide show. For greater understanding, the teacher may want to play the slide show as he/she reads the background section. For the students, the slide show can be used in its entirety or can be edited as necessary for a given class. What Is p53 and Where Is the Gene Located? While commonly known as p53, the official name of this gene is Tumor Protein p53 and its official symbol is TP53. TheTP53 gene codes for the TP53 (p53) protein which acts as a tumor suppressor and works in response to DNA damage to orchestrate the repair of damaged DNA. If the DNA cannot be repaired, the p53 protein prevents the cell from dividing and signals it to undergo apoptosis (programmed cell death). The name p53 is due to protein’s 53 kilo-Dalton molecular mass. The gene which codes for this protein is located on the short (p) arm of chromosome 17 at position 13.1 (17p13.1). The gene begins at base pair 7,571,719 and ends at base pair 7, 590,862 making it 19,143 base pairs long. (1, 2) What Does the p53 Gene Look Like When Translated Into Protein? The TP53 gene has 11 exons and a very large 10 kb intron between exons 1 and 2. In humans, exon 1 is non-coding and it has been shown that this region could form a stable stem-loop structure which binds tightly to normal p53 but not to mutant p53 proteins.
    [Show full text]
  • The NF2 Tumor Suppressor Merlin Interacts with Ras and Rasgap, Which May Modulate Ras Signaling
    Oncogene (2019) 38:6370–6381 https://doi.org/10.1038/s41388-019-0883-6 ARTICLE The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling 1 1 2 1 1 1 Yan Cui ● Susann Groth ● Scott Troutman ● Annemarie Carlstedt ● Tobias Sperka ● Lars Björn Riecken ● 2 3 1 Joseph L. Kissil ● Hongchuan Jin ● Helen Morrison Received: 5 July 2018 / Revised: 31 March 2019 / Accepted: 1 May 2019 / Published online: 16 July 2019 © The Author(s) 2019. This article is published with open access Abstract Inactivation of the tumor suppressor NF2/merlin underlies neurofibromatosis type 2 (NF2) and some sporadic tumors. Previous studies have established that merlin mediates contact inhibition of proliferation; however, the exact mechanisms remain obscure and multiple pathways have been implicated. We have previously reported that merlin inhibits Ras and Rac activity during contact inhibition, but how merlin regulates Ras activity has remained elusive. Here we demonstrate that merlin can directly interact with both Ras and p120RasGAP (also named RasGAP). While merlin does not increase the catalytic activity of RasGAP, the interactions with Ras and RasGAP may fine-tune Ras signaling. In vivo, loss of RasGAP in 1234567890();,: 1234567890();,: Schwann cells, unlike the loss of merlin, failed to promote tumorigenic growth in an orthotopic model. Therefore, modulation of Ras signaling through RasGAP likely contributes to, but is not sufficient to account for, merlin’s tumor suppressor activity. Our study provides new insight into the mechanisms of merlin-dependent Ras regulation and may have additional implications for merlin-dependent regulation of other small GTPases. Introduction ependymomas, and astrocytomas [1].
    [Show full text]
  • Cancer Biology Introduction Proto-Oncogenes Tumor
    Introduction • Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell Cancer Biology death) of each of its constituent members except its stem cells • A tumor arises as a result of uncontrolled cell division and failure for self-elimination Chapter 18 • Alterations in three groups of genes are responsible Eric J. Hall., Amato Giaccia, for the deregulated control mechanisms that are the hallmarks of cancer cells: proto-oncogenes, tumor- Radiobiology for the Radiologist supressor genes, and DNA stability genes Proto-oncogenes Tumor-suppressor genes • Proto-oncogenes are components of signaling • Tumor-suppressor genes are also components of networks that act as positive growth the same signaling networks as proto-oncogenes, except that they act as negative growth regulators regulators in response to mitogens, cytokines, • They modulate proliferation and survival by and cell-to-cell contact antagonizing the biochemical functions of proto- • A gain-of-function mutation in only one copy oncogenes or responding to unchecked growth signals of a protooncogene results in a dominantly • In contrast to oncogenes, inactivation of both acting oncogene that often fails to respond to copies of tumor-suppressor genes is required for extracellular signals loss of function in most cases DNA stability genes Mechanisms of carcinogenesis • DNA stability genes form a class of genes • A single genetic alteration that leads to the involved in both monitoring and activation of an oncogene or loss of a tumor maintaining
    [Show full text]
  • Expression of a Down-Regulated Target, Ssecks, Reverses V-Jun-Induced Transformation of 10T1/2 Murine ®Broblasts
    Oncogene (2001) 20, 141 ± 146 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc ORIGINAL PAPERS Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine ®broblasts Steven B Cohen1, Anke Waha2, Iwin H Gelman3 and Peter K Vogt*,2 1Gen-Probe Incorporated, 10210 Genetic Center Drive, San Diego, California CA 92121, USA; 2Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California CA 92037, USA; 3Department of Microbiology, Mount Sinai School of Medicine, New York, NY 10029-6574, USA Line 10T1/2 mouse ®broblast overexpressing the v-Jun its cellular counterpart by a 27-amino acid deletion and oncoprotein were morphologically altered, grew into by two amino acid substitutions (Nishimura and Vogt, multilayered foci in culture and formed colonies when 1988). These mutations synergize to make Jun suspended in agar. The growth rate of the v-Jun- independent of cellular regulation and to turn it into transformed 10T1/2 cells was not changed signi®cantly a strong growth promoter (Abate et al., 1990; Boyle et from that of the untransformed parental cells, but the al., 1991; Chida and Vogt, 1992; Hibi et al., 1993; saturation density of the transformed cultures exceeded Morgan et al., 1993; 1994). that of normal controls by a factor of 2. mRNA v-Jun induces oncogenic transformation by aberrant extracted from v-Jun-transformed 10T1/2 cells was regulation of speci®c target genes. The dierential analysed for dierential gene expression with DNA expression of these targets determines the neoplastic micro-array technology.
    [Show full text]
  • The Functional Loss of the Retinoblastoma Tumour Suppressor
    Available online http://breast-cancer-research.com/content/10/5/R75 ResearchVol 10 No 5 article Open Access The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas Jason I Herschkowitz1,2,4, Xiaping He1,2, Cheng Fan1 and Charles M Perou1,2,3 1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA 2Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA 3Department of Pathology & Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA 4Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, DeBakey M635, Houston, TX 77030, USA Corresponding author: Charles M Perou, [email protected] Received: 19 Jun 2008 Revisions requested: 31 Jul 2008 Revisions received: 22 Aug 2008 Accepted: 9 Sep 2008 Published: 9 Sep 2008 Breast Cancer Research 2008, 10:R75 (doi:10.1186/bcr2142) This article is online at: http://breast-cancer-research.com/content/10/5/R75 © 2008 Herschkowitz et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Introduction Breast cancers can be classified using whole Results RB1 loss of heterozygosity was observed at an overall genome expression into distinct subtypes that show differences frequency of 39%, with a high frequency in basal-like (72%) and in prognosis. One of these groups, the basal-like subtype, is luminal B (62%) tumours.
    [Show full text]
  • Utimmunohistochemical Detection of the Alternate Ink4a-Encoded
    utImmunohistochemical Detection of the Alternate INK4a-Encoded Tumor Suppressor Protein p14ARF in Archival Human Cancers and Cell Lines Using Commercial Antibodies: Correlation with p16INK4a Expression Joseph Geradts, M.D., Robb E. Wilentz, M.D., Helen Roberts, B.Sc. Nuffield Department of Clinical Laboratory Sciences (JG, HR), University of Oxford, John Radcliffe Hospital, Oxford, UK; and Department of Pathology (REW), The Johns Hopkins University School of Medicine, Baltimore, Maryland KEY WORDS: Antibodies, Immunohistochemistry, The INK4a locus encodes two structurally unrelated INK4a, p14ARF, p16INK4a. tumor suppressor proteins, p16INK4a and p14ARF. Mod Pathol 2001;14(11):1162–1168 Although the former is one of the most common targets for inactivation in human neoplasia, the fre- The INK4a gene on chromosome 9p21 is one of the quency of p14ARF abrogation is not established. We most common targets for inactivation in human have developed an immunohistochemical assay neoplasia. The gene is unusual in that it encodes that allows the evaluation of p14ARF expression in two structurally unrelated proteins, p16INK4a and formalin-fixed, paraffin-embedded tissues, using p14ARF, the human homologue of murine p19ARF. commercially available antibodies. p14ARF positive Two different first exons are spliced in different cells showed nuclear/nucleolar staining, which was reading frames to common exon 2 (1). p16INK4a acts absent in all cell lines and tumors with homozygous as a retinoblastoma protein (pRB) agonist by inhib- deletions of the INK4a gene. The assay was applied iting the phosphorylation of pRB by activated to 34 paraffin-embedded cell buttons, 30 non-small cyclin-dependent kinases 4 and 6 (2). The principal INK4a cell lung cancers and 28 pancreatic carcinomas, and methods of p16 inactivation are homozygous the staining results were correlated with p16INK4a deletion of the gene, promoter methylation of exon ARF 1␣, and intragenic mutation (3).
    [Show full text]
  • Cancer Genes & Cancer Genetics
    Cancer Genes & Cancer Genetics NO office hours this Friday (5-1). Please set up an appointment if you any questions. [email protected] READING: pp. 202-220 Somatic Cells/Germ line mutations This nothing to do with + bugs Mutations passed on to progeny, all tissues, Mendelian Mutations usually little effect, cell death GERM LINE for damaged female: eggs cell; however, all cancers arise from somatic cell (precursors) mutation, one cell confined male: sperm to one tissue SOMATIC CELLS embryo proper all tissues GO STOP Cell Proliferation and Death STOP GO + Uncontrolled cell Cell division comes from suicide accumulation of (programmed cell death) genetic defects that lead to too much "go" signal, too little "stop" signal, and loss of cell suicide proliferation and programmed cell death tightly regulated to ensure the integrity of organs and tissues Checkpoint The Cell Cycle Mitosis (M-phase) STOP GO M G2 G1 S G1 G2 S STOP Checkpoint tumor suppressors (-) STOP proto-oncogenes (+) GO Checkpoints ensure the cell cycle proceeds without errors Cancer Genes Accumulation of multiple mutations Potential cancer genes - about 100 (0.3% of total) genes Inappropriate signals about need for cell division (hormonal signaling pathways: growth factors) GO Malfunctions in (CDK-cyclin) complexes controlling cell cycle transitions STOP Checkpoint breakdowns leading to DNA instability Loss of programmed cell death (cell suicide) Invasion/Metastasis Part 1: Tumor Suppressor Genes Loss-of-Function (LOF) Function no checkpoint stop; no DNA repair; STOP signal
    [Show full text]